拉贝洛尔在新西兰的多中心开放试验。

A multicentre open trial of labetalol in New Zealand.

出版信息

Br J Clin Pharmacol. 1979;8(Suppl 2):179S-182S.

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1429757/

Abstract

1 In a multicentre open trial, labetalol was given to 128 patients in ten centres. Forty-three patients had not previously received antihypertensive therapy; the remainder (85 patients) had been on antihypertensive therapy with either unsatisfactory BP control or troublesome side-effects. 2 Thirty-two patients were withdrawn from the trial in the first 6 months of therapy, 24 (19% of the total) because of side-effects. 3 Control of BP was generally satisfactory or considerably improved. Other drugs (usually a diuretic) had to be added in 23 patients. 4 There was an abnormality of liver function in one patient; otherwise there were no biochemical or haematological problems.

摘要

在一项多中心开放试验中，10个中心的128例患者接受了拉贝洛尔治疗。43例患者此前未接受过抗高血压治疗；其余85例患者曾接受抗高血压治疗，但血压控制不理想或出现了令人困扰的副作用。2. 在治疗的前6个月，32例患者退出试验，其中24例（占总数的19%）是由于副作用。3. 血压控制总体令人满意或有显著改善。23例患者不得不加用其他药物（通常是利尿剂）。4. 1例患者出现肝功能异常；除此之外，未出现生化或血液学问题。